Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway

References

• Bahadoram S, Davoodi M, Hassanzadeh S, et al. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39(3):1–16
   Google Scholar
• Cardenas LM, Deluce JE, Khan S, et al. Next wave of targets in the treatment of advanced renal cell carcinoma. Curr Oncol. 2022;29(8):5426–5441. doi: 10.3390/curroncol29080429.
   PubMed Web of Science ®Google Scholar
• Takagi T. Optimization of first-line systemic therapy in patients with advanced clear cell renal cell carcinoma. Int J Urol. 2023;30(9):705–713. doi: 10.1111/iju.15103.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Kaelin WG. Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26(10):1519–1530. doi: 10.1038/s41591-020-1093-z.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Msaouel P, Ross JA, et al. Temsirolimus versus pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: a randomized phase II trial. Eur Urol Oncol. 2020;3(5):687–694. doi: 10.1016/j.euo.2019.06.004.
   PubMed Web of Science ®Google Scholar
• Hahn AW, Klaassen Z, Agarwal N, et al. First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2019;2(6):708–715. doi: 10.1016/j.euo.2019.09.002.
   PubMed Web of Science ®Google Scholar
• Duran I, Lambea J, Maroto P, et al. Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action. Target Oncol. 2017;12(1):19–35. doi: 10.1007/s11523-016-0463-4.
   PubMed Web of Science ®Google Scholar
• Wilson NR, Wiele AJ, Surasi DS, et al. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021;19(6):e401–e8. doi: 10.1016/j.clgc.2021.08.007.
   PubMed Web of Science ®Google Scholar
• Agashe RP, Lippman SM, Kurzrock R. JAK: not just another kinase. Mol Cancer Ther. 2022;21(12):1757–1764. doi: 10.1158/1535-7163.MCT-22-0323.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Orouei S, et al. STAT3 pathway in gastric cancer: signalling, therapeutic targeting and future prospects. Biology (Basel). 2020;9(6):1–36. doi: 10.3390/biology9060126.
   Google Scholar
• Ashrafizadeh M, Gholami MH, Mirzaei S, et al. Dual relationship between long non-coding RNAs and STAT3 signalling in different cancers: new insight to proliferation and metastasis. Life Sci. 2021;270:119006. doi: 10.1016/j.lfs.2020.119006.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Mohan CD, Rangappa S, et al. Noncoding RNAs as regulators of STAT3 pathway in gastrointestinal cancers: roles in cancer progression and therapeutic response. Med Res Rev. 2023;43(5):1263–1321. doi: 10.1002/med.21950.
   PubMed Web of Science ®Google Scholar
• Perner F, Perner C, Ernst T, et al. Roles of JAK2 in aging, inflammation, haematopoiesis and malignant transformation. Cells. 2019;8(8):854. doi: 10.3390/cells8080854.
   PubMed Web of Science ®Google Scholar
• Wilks AF. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol. 2008;19(4):319–328. doi: 10.1016/j.semcdb.2008.07.020.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol. 2022;15(8):671–684. doi: 10.1080/17474086.2022.2112565.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4(5):652–659. doi: 10.1001/jamaoncol.2017.5818.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Savona MR, Scott BL, et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020;4(22):5825–5835. doi: 10.1182/bloodadvances.2020003314.
   PubMed Web of Science ®Google Scholar
• Jeon JY, Zhao Q, Buelow DR, et al. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Invest New Drugs. 2020;38(2):340–349. doi: 10.1007/s10637-019-00786-4.
   PubMed Web of Science ®Google Scholar
• Jensen KV, Cseh O, Aman A, et al. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumour initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One. 2017;12(12):e0189670. doi: 10.1371/journal.pone.0189670.
   PubMed Web of Science ®Google Scholar
• Ochi N, Isozaki H, Takeyama M, et al. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung cancer. Exp Cell Res. 2016;344(2):194–200. doi: 10.1016/j.yexcr.2016.05.008.
   PubMed Web of Science ®Google Scholar
• Doheny D, Sirkisoon S, Carpenter RL, et al. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumour growth, and metastasis. Oncogene. 2020;39(42):6589–6605. doi: 10.1038/s41388-020-01454-1.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu S, Deng P, et al. Targeting the IRAK1-S100A9 axis overcomes resistance to paclitaxel in nasopharyngeal carcinoma. Cancer Res. 2021;81(5):1413–1425. doi: 10.1158/0008-5472.CAN-20-2125.
   PubMed Web of Science ®Google Scholar
• Yadav B, Wennerberg K, Aittokallio T, et al. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504–513. doi: 10.1016/j.csbj.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Clarke R. Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. Breast Cancer Res Treat. 1997;46(2-3):255–278. doi: 10.1023/a:1005938428456.
   PubMed Web of Science ®Google Scholar
• Brodaczewska KK, Szczylik C, Fiedorowicz M, et al. Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016;15(1):83. doi: 10.1186/s12943-016-0565-8.
   PubMedGoogle Scholar
• Kontos CK, Christodoulou MI, Scorilas A. Apoptosis-related BCL2-family members: key players in chemotherapy. Anticancer Agents Med Chem. 2014;14(3):353–374. doi: 10.2174/18715206113139990091.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Hart S, Goh KC, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2012;2(5):e69–e69. doi: 10.1038/bcj.2012.14.
   PubMedGoogle Scholar
• Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib. Recent Results Cancer Res. 2018;212:119–132. doi: 10.1007/978-3-319-91439-8_6.
   PubMedGoogle Scholar
• Makhov P, Joshi S, Ghatalia P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17(7):1355–1364. doi: 10.1158/1535-7163.MCT-17-1299.
   PubMed Web of Science ®Google Scholar
• Shao F, Pang X, Baeg GH. Targeting the JAK/STAT signalling pathway for breast cancer. Curr Med Chem. 2021;28(25):5137–5151. doi: 10.2174/0929867328666201207202012.
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signalling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. doi: 10.1038/s41392-021-00791-1.
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukaemia. Blood Cancer J. 2011;1(11):e44–e44. doi: 10.1038/bcj.2011.43.
   PubMedGoogle Scholar
• Mori S, Chang JT, Andrechek ER, et al. Anchorage-independent cell growth signature identifies tumours with metastatic potential. Oncogene. 2009;28(31):2796–2805. doi: 10.1038/onc.2009.139.
   PubMed Web of Science ®Google Scholar
• Wang S. Anchorage-independent growth of prostate cancer stem cells. Methods Mol Biol. 2009;568:151–160. doi: 10.1007/978-1-59745-280-9_9.
   PubMedGoogle Scholar
• Oh Y, Lee JS, Lee JS, et al. JAK2 inhibitor, fedratinib, inhibits P-gp activity and Co-Treatment induces cytotoxicity in antimitotic Drug-Treated P-gp overexpressing resistant KBV20C cancer cells. Int J Mol Sci. 2022;23(9):4597. doi: 10.3390/ijms23094597.
   PubMed Web of Science ®Google Scholar
• Britschgi A, Andraos R, Brinkhaus H, et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012;22(6):796–811. doi: 10.1016/j.ccr.2012.10.023.
   PubMed Web of Science ®Google Scholar
• Hosseini MM, Kurtz SE, Abdelhamed S, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukaemia subtypes. Leukemia. 2018;32(11):2374–2387. doi: 10.1038/s41375-018-0112-2.
   PubMed Web of Science ®Google Scholar
• Campbell GR, Rawat P, Spector SA. Pacritinib inhibition of IRAK1 blocks aberrant TLR8 signalling by SARS-CoV-2 and HIV-1-Derived RNA. J Innate Immun. 2022;96–106. doi: 10.1159/000525292.
   PubMed Web of Science ®Google Scholar
• Regenbogen T, Chen L, Trinkaus K, et al. Pacritinib to inhibit JAK/STAT signalling in refractory metastatic Colon and rectal cancer. J Gastrointest Oncol. 2017;8(6):985–989. doi: 10.21037/jgo.2017.08.16.
   PubMed Web of Science ®Google Scholar